VALENSCION
Dead / Abandoned — Abandoned — no statement of use filed (as of 10 Oct 2022)
What this means for you
This application is over — abandoned 10 Oct 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88056116
- Mark type
- Stylized text
- Filed
- 27 Jul 2018
- Published for opposition
- 09 Jul 2019
- Abandoned
- 10 Oct 2022
- Attorney of record
- John V. Hobgood, Esquire
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for use in the treatment of viral infection, bacterial infection, asthma, allergies, cancer, transplant rejection, inflammatory diseases and disorders, immune diseases and disorders, hereditary diseases and disorders, namely, metabolic, endocrine, neurologic and cardiovascular diseases or disorders, and auto immune diseases and disorders; pharmaceuticals for use in the treatment of T-cell and B-cell leukemias and lymphomas; medical therapeutic preparations, namely, biologically active modulators, biologically active immune modulators, biologically active antisense DNA or RNA compounds, chemical modulators of gene expression working at DNA transcription, RNA or translation processes; immunomodulatory oligonucleotides, namely, ingredients that enhance or induce an immune response as a component part in a pharmaceutical preparation; pharmaceutical and vaccine adjuvants to enhance the immune system response; medical therapeutic preparations, namely, small molecule chemicals aimed at inhibiting cellular proteins
- Class 042 — Scientific and technological services: Medical research; scientific research; biological research; chemical research; pharmaceutical research services; pharmaceutical research and development; product research and development; medical and scientific research in the area of oligonucleotides or chemical products; medical and scientific research in the area of the structure-based drug design; biological and chemical research in the field of immunology, virology, oncology and hereditary diseases; medical and scientific research in the area of small molecule chemicals aimed at inhibiting cellular proteins for use as therapeutic agents; pharmaceutical research and development in the field of infectious diseases and disorders, cancer, viral diseases and disorders, inflammatory diseases and disorders, immunological diseases and disorders, autoimmune diseases and disorders, hereditary diseases and disorders, and cardiovascular diseases and disorders
Owner
- Idera Pharmaceuticals, Inc., Exton, PA, US
- Idera Pharmaceuticals, Inc., Exton, PA, US
Prosecution history
- 11 Oct 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 10 Oct 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 24 Feb 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Feb 2022 — SOU EXTENSION 5 GRANTED
- 16 Feb 2022 — SOU EXTENSION 5 FILED
- 23 Feb 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 16 Feb 2022 — SOU TEAS EXTENSION RECEIVED
- 01 Sept 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 Aug 2021 — SOU EXTENSION 4 GRANTED
- 30 Aug 2021 — SOU EXTENSION 4 FILED
- 30 Aug 2021 — SOU TEAS EXTENSION RECEIVED
- 05 Mar 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Mar 2021 — SOU EXTENSION 3 GRANTED
- 03 Mar 2021 — SOU EXTENSION 3 FILED
- 03 Mar 2021 — SOU TEAS EXTENSION RECEIVED